ArticleResearch in pharmaceutical sciences2026
Exosomes from induced and adipose-derived MSCs regulate NRK-52E cells under hyperglycemic conditions.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Diabetic nephropathy (DN) is a major complication of diabetes mellitus (DM), primarily driven by chronic hyperglycemia and characterized by progressive renal damage. The regenerative potential of mesenchymal stem cell (MSC)-derived exosomes (Exos) has been highlighted. However, the therapeutic effects of Exos derived from induced MSCs (iMSC-Exos) and adipose-derived MSC (ADMSC-Exos) on DN-associated cellular processes remain largely unexplored. Experimental approach: Exos were isolated from iMSCs, ADMSCs, and human gingival fibroblasts (HGF). NRK-52E cells were treated with Exos under normal glucose (NG) and high glucose (HG) conditions. Cell viability, apoptosis, reactive oxygen species (ROS) levels, mitochondrial membrane potential (MMP), and the expression of antioxidant-related genes ( Findings/Results: Under NG conditions, Exos enhanced NRK-52E cellular viability. However, under HG conditions, all types of Exos exhibited diminished effects at 24 h, and only ADMSC-Exos and HGF-Exos significantly promoted viability at 48 h. Exos did not significantly alter ROS levels but affected mitochondrial function and the expression of antioxidant-related genes. Specifically, while both ADMSC- and iMSC-Exos enhanced MMP under NG conditions, ADMSC-Exos reduced MMP under HG conditions, and iMSC-Exos consistently enhanced it. Under NG conditions, both iMSC- and ADMSC-Exos upregulated Conclusion and implications: The findings highlighted the distinct roles of iMSC-Exos and ADMSC-Exos, with both showing limited efficacy under HG. However, iMSC-Exos enhanced mitochondrial function under HG, suggesting a potential therapeutic benefit that requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.